No abstract

.

No abstract

Background: Rheumatic immune-related adverse events (irAEs) are associated with better tumour response to immune checkpoint inhibitors (ICI). Research on this immunological intersection between malignancies and rheumatic and musculoskeletal diseases (RMDs) offers the opportunity for better patient centred care and scientific progress. A registry-based study is an ideal approach to obtain real world data on characteristics and optimal clinical management of rheumatic irAEs. Methods:The TRheuMa registry is a prospective long-term observational study of a patient cohort suffering from rheumatic side effects of cancer therapies and is part of the large MalheuR project initiated in July 2018 at the University Hospital Heidelberg to explore interrelations of malignancies and RMDs.

La analogía entre Dios y las criaturas según Sto. Tomás